<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02830776</url>
  </required_header>
  <id_info>
    <org_study_id>833277-1</org_study_id>
    <nct_id>NCT02830776</nct_id>
  </id_info>
  <brief_title>Topical Bimatoprost for Chemical Blepharoplasty</brief_title>
  <official_title>Topical Bimatoprost for Chemical Blepharoplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tulane University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Topical bimatoprost has been shown to cause periorbital changes of soft tissue which are most&#xD;
      pronounced when used directly onto the cornea for the treatment of glaucoma. Changes are&#xD;
      primarily felt to be the result of prostaglandin-mediated adipocyte loss, resulting in&#xD;
      deepening of the upper eyelid sulcus and recession of infraorbital pseudoherniation. Use of&#xD;
      topical bimatoprost to the upper eyelid margin, now FDA approved for eyelash enhancement, may&#xD;
      provide a metered effect on the periocular tissues and allow for a topical approach to&#xD;
      periocular rejuvenation.&#xD;
&#xD;
      This is a proof of concept study which aims to enroll a series of patients with mild to&#xD;
      severe dermatochalasis, treat with topical bimatoprost 0.03% solution to the upper lid&#xD;
      margin, and evaluate for cosmetic improvement of the periocular area.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perception of beauty in the periocular region is influenced by several factors, including&#xD;
      symmetry, population norms, and skin texture and tone. Soft tissue and skin changes over time&#xD;
      create an aged appearance with the development of dermatochalasis, blepharoptosis, lacrimal&#xD;
      gland prolapse, and fat prolapse. Techniques for periocular rejuvenation are well established&#xD;
      and include soft tissue augmentation, resurfacing, and surgical correction. In May 2015,&#xD;
      Sarnoff and Gotkin reported a case of &quot;chemical blepharoplasty&quot; achieved with topical&#xD;
      bimatoprost ophthalmic 0.03% solution applied to the upper eyelid margin. After three months&#xD;
      of use, the author noted a more youthful appearance of the periocular region, with deepening&#xD;
      of the upper eyelid sulcus, reduction in dermatochalasis, and diminution of the inferior&#xD;
      eyelid fat pad. These changes were attributed to the prostaglandin associated periorbitopathy&#xD;
      (PAP), a well described phenomenon observed with the use of topical prostaglandin analogues&#xD;
      use for glaucoma.&#xD;
&#xD;
      Periorbital changes observed with topical prostaglandin analogues are primarily due to&#xD;
      effects on aponeurotic and deep orbital adipocytes. Prostaglandins activate the adipocyte&#xD;
      mitogen-activated protein kinase (MAPK) pathway, leading to inactivation of peroxisome&#xD;
      proliferator-activated receptor (PPAR)-gamma, inhibition of adipocyte differentiation, and&#xD;
      decreased fat accumulation within adipocytes. Bimatoprost concentration-dependent&#xD;
      contractions of ciliary muscles and activation of matrix metalloproteinases may also&#xD;
      contribute to periocular changes. Patients using topical ophthalmic prostaglandin analogues&#xD;
      commonly develop periorbital fat loss, which has been well characterized in the ophthalmology&#xD;
      literature.&#xD;
&#xD;
      Bimatoprost applied to the upper eyelid margin for eyelash enhancement attempts to capitalize&#xD;
      on the desirable effects of darker, longer, thicker eyelashes, while limiting more&#xD;
      significant and undesirable effects through limited exposure of the drug to ocular tissues.&#xD;
      This same concept may apply for dermatochalasis: at a metered dose, topical bimatoprost to&#xD;
      the lid margin could lead to subtle periorbital fat loss resulting in improved&#xD;
      dermatochalasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">April 30, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graded Change in Dermatochalasis</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>Patients were followed for 12 weeks total, with visits every 4 weeks for a total of 4 visits. Photodocumentation was performed at each visit. At completion of the study period, each patient's photographs at weeks 0 and 12, were graded by 2 blinded evaluators for level of dermatochalasis: -1 (deep upper eyelid sulcus), 0 (no dermatochalasis), 1 (mild, slightly noticeable), 2 (moderate, noticeable), or 3 (severe, distinctive). The change of dermatochalasis (week 12 score subtracted from week 0 score) was the primary outcome measure. A greater change (based on a higher score) in dermatochalasis indicated better response to the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Satisfaction</measure>
    <time_frame>Weeks 0, 12</time_frame>
    <description>Entry and exit surveys were completed about self perception of the periocular area. The satisfaction was measured based on 2 short surveys. Entry survey had 1 question &quot;how do you rate your satisfaction with your appearance?&quot; - the scale was 0-5, with 0 being &quot;Not at all&quot; to 5 being &quot;extremely.&quot; The exit survey posed two questions, (1) &quot;how do you rate satisfaction with your appearance?&quot; with the same 0-5 scale, as well as (2) Do you notice an improvement in your eyelid droop (dermatochalasis)?&quot; with a scale as follows: Worse (-1), No Change (0), 25% better (1), 50% better (2), 75% better (3), or 100% better (4). The change in satisfaction was measured by the summation of scores from both surveys and the average was calculated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Dermatochalasis</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single-arm open label proof of concept pilot study evaluating use of Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost 0.03% ophthalmic solution</intervention_name>
    <description>Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>Latisse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18+,&#xD;
&#xD;
          -  mild to severe dermatochalasis, desire for enhanced eyelashes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with current use of ophthalmic prostaglandin analogues,&#xD;
&#xD;
          -  history of blepharoplasty,&#xD;
&#xD;
          -  history of neuromodulators or fillers to the periocular region or frontalis in the&#xD;
             last 6 months,&#xD;
&#xD;
          -  existing deep upper eyelid sulcus,&#xD;
&#xD;
          -  opposition to eyelash enhancement,&#xD;
&#xD;
          -  pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Megan P Couvillion, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University School of Medicine, Department of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tulane Department of Dermatology</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sarnoff DS, Gotkin RH. Bimatoprost-induced chemical blepharoplasty. J Drugs Dermatol. 2015 May;14(5):472-7.</citation>
    <PMID>25942665</PMID>
  </reference>
  <reference>
    <citation>Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthalmic Plast Reconstr Surg. 2008 Jul-Aug;24(4):302-7. doi: 10.1097/IOP.0b013e31817d81df.</citation>
    <PMID>18645437</PMID>
  </reference>
  <reference>
    <citation>Reginato MJ, Krakow SL, Bailey ST, Lazar MA. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J Biol Chem. 1998 Jan 23;273(4):1855-8.</citation>
    <PMID>9442016</PMID>
  </reference>
  <reference>
    <citation>Kucukevcilioglu M, Bayer A, Uysal Y, Altinsoy HI. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin Exp Ophthalmol. 2014 Mar;42(2):126-31. doi: 10.1111/ceo.12163. Epub 2013 Aug 4.</citation>
    <PMID>23844550</PMID>
  </reference>
  <reference>
    <citation>Cohen JL. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. Dermatol Surg. 2010 Sep;36(9):1361-71. doi: 10.1111/j.1524-4725.2010.01522.x. Review.</citation>
    <PMID>20384750</PMID>
  </reference>
  <reference>
    <citation>Shah M, Lee G, Lefebvre DR, Kronberg B, Loomis S, Brauner SC, Turalba A, Rhee DJ, Freitag SK, Pasquale LR. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013 May 1;8(5):e61638. doi: 10.1371/journal.pone.0061638. Print 2013.</citation>
    <PMID>23650502</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 7, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <results_first_submitted>January 14, 2021</results_first_submitted>
  <results_first_submitted_qc>February 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2021</results_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dermatochalasis</keyword>
  <keyword>bimatoprost</keyword>
  <keyword>blepharoplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cutis Laxa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 26, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT02830776/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 4, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT02830776/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One patient enrolled in the study but was lost to followup. Data was incomplete for this subject so was not included in final analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>This is a single-arm open label proof of concept pilot study evaluating use of Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping).&#xD;
bimatoprost 0.03% ophthalmic solution: Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>Patients received Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="37" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Graded Change in Dermatochalasis</title>
        <description>Patients were followed for 12 weeks total, with visits every 4 weeks for a total of 4 visits. Photodocumentation was performed at each visit. At completion of the study period, each patient's photographs at weeks 0 and 12, were graded by 2 blinded evaluators for level of dermatochalasis: -1 (deep upper eyelid sulcus), 0 (no dermatochalasis), 1 (mild, slightly noticeable), 2 (moderate, noticeable), or 3 (severe, distinctive). The change of dermatochalasis (week 12 score subtracted from week 0 score) was the primary outcome measure. A greater change (based on a higher score) in dermatochalasis indicated better response to the treatment.</description>
        <time_frame>At 12 weeks</time_frame>
        <population>Patients received Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Patients received Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)</description>
          </group>
        </group_list>
        <measure>
          <title>Graded Change in Dermatochalasis</title>
          <description>Patients were followed for 12 weeks total, with visits every 4 weeks for a total of 4 visits. Photodocumentation was performed at each visit. At completion of the study period, each patient's photographs at weeks 0 and 12, were graded by 2 blinded evaluators for level of dermatochalasis: -1 (deep upper eyelid sulcus), 0 (no dermatochalasis), 1 (mild, slightly noticeable), 2 (moderate, noticeable), or 3 (severe, distinctive). The change of dermatochalasis (week 12 score subtracted from week 0 score) was the primary outcome measure. A greater change (based on a higher score) in dermatochalasis indicated better response to the treatment.</description>
          <population>Patients received Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".2679" lower_limit="0.0970" upper_limit="0.4387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient Satisfaction</title>
        <description>Entry and exit surveys were completed about self perception of the periocular area. The satisfaction was measured based on 2 short surveys. Entry survey had 1 question &quot;how do you rate your satisfaction with your appearance?&quot; - the scale was 0-5, with 0 being &quot;Not at all&quot; to 5 being &quot;extremely.&quot; The exit survey posed two questions, (1) &quot;how do you rate satisfaction with your appearance?&quot; with the same 0-5 scale, as well as (2) Do you notice an improvement in your eyelid droop (dermatochalasis)?&quot; with a scale as follows: Worse (-1), No Change (0), 25% better (1), 50% better (2), 75% better (3), or 100% better (4). The change in satisfaction was measured by the summation of scores from both surveys and the average was calculated.</description>
        <time_frame>Weeks 0, 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>This is a single-arm open label proof of concept pilot study evaluating use of Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping).&#xD;
bimatoprost 0.03% ophthalmic solution: Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient Satisfaction</title>
          <description>Entry and exit surveys were completed about self perception of the periocular area. The satisfaction was measured based on 2 short surveys. Entry survey had 1 question &quot;how do you rate your satisfaction with your appearance?&quot; - the scale was 0-5, with 0 being &quot;Not at all&quot; to 5 being &quot;extremely.&quot; The exit survey posed two questions, (1) &quot;how do you rate satisfaction with your appearance?&quot; with the same 0-5 scale, as well as (2) Do you notice an improvement in your eyelid droop (dermatochalasis)?&quot; with a scale as follows: Worse (-1), No Change (0), 25% better (1), 50% better (2), 75% better (3), or 100% better (4). The change in satisfaction was measured by the summation of scores from both surveys and the average was calculated.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".214" lower_limit="-.777" upper_limit=".349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>This is a single-arm open label proof of concept pilot study evaluating use of Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping).&#xD;
bimatoprost 0.03% ophthalmic solution: Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <description>Itching at the site of application</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Eyelid skin redness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Eyelid darkening</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Unexpected hair growth</sub_title>
                <description>Facial pigmented hair growth beyond the eyelashes</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Megan Couvillion, MD, FAAD</name_or_title>
      <organization>Formerly - Tulane University Department of Dermatology. Currently - Suzanne Bruce and Associates, PA</organization>
      <phone>504-473-2915</phone>
      <email>megan.couvillion@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

